Evidence map›Paper›PMID 33839311›Full record

Trial reportInfection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases2021

Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection.

Taimour Langaee, Mohammad H Al-Shaer, Yan Gong, Elizabeth Lima, Sampson Antwi, Anthony Enimil, Albert Dompreh, Hongmei Yang, Wael A Alghamdi, Lubbe Wiesner and 2 more

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

Taimour LangaeeCollege of Pharmacy, Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, University of Florida, Gainesville, FL, United States.
Mohammad H Al-ShaerDepartment of Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL, United States.
Yan GongCollege of Pharmacy, Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, University of Florida, Gainesville, FL, United States.
Elizabeth LimaCollege of Pharmacy, Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, University of Florida, Gainesville, FL, United States; Ohio State University, Columbus, OH, United States.
Sampson AntwiDirectorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana; Department of Child Health, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Anthony EnimilDirectorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana; Department of Child Health, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Albert DomprehSerology Unit, Department of Clinical Microbiology, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Hongmei YangDepartment of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States.
Wael A AlghamdiDepartment of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
Lubbe WiesnerDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Charles A PeloquinDepartment of Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL, United States.
Awewura KwaraDepartment of Medicine, College of Medicine, University of Florida, Gainesville, FL, United States. Electronic address: awewura.kwara@medicine.ufl.edu.
University of Florida · USKwame Nkrumah University of Science and Technology · GHKing Khalid University · SAKomfo Anokye Teaching Hospital · GHThe Ohio State University · USUniversity of Cape Town · ZAUniversity of Rochester · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupU01AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI JACKSON, J BROOKS · 2006 to 2010
$109.7M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
Virology/Immunology CoreP30AI078498 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2008 to 2018
$14.6M
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in ChildrenR01HD071779 · NICHD · UNIVERSITY OF FLORIDA · PI KWARA, AWEWURA JACOB · 2012 to 2022
$6.0M
NIAID NIH HHS P30 AI078498NIAID NIH HHS U01 AI068632NIAID NIH HHS U01 AI068634NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NICHD NIH HHS R01 HD071779
6 · The paper itself

Abstract

Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor that is used in the treatment of human immunodeficiency virus (HIV) infection in children younger than 3 years old. Identifying genetic predictors of NVP pharmacokinetics (PK) in young children is important because inter-individual variability in NVP concentrations contributes to variable treatment response and the information may be used to individualize dosing decisions. We examined the relationship between genetic variations in relevant drug disposition genes and NVP PK parameters in Ghanaian children living with HIV eligible to initiate NVP-based antiretroviral therapy. Participants received NVP plus zidovudine and lamivudine or abacavir and lamivudine twice daily, and those with tuberculosis (TB) coinfection received concurrent anti-TB therapy with NVP. Pharmacokinetic sampling was performed after at least 4 weeks of antiretroviral therapy. Nevirapine minimum concentration (C

Indexed as

Anti-HIV AgentsChild, PreschoolCoinfectionCytochrome P-450 CYP2B6FemaleGhanaHIV InfectionsHumansInfantLamivudineMaleNevirapinePharmacogeneticsPolymorphism, Single NucleotideReverse Transcriptase InhibitorsTuberculosisAnti-HIV AgentsCytochrome P-450 CYP2B6LamivudineNevirapineReverse Transcriptase InhibitorsCYP2B6CYP3A4NevirapineNuclear receptorsPharmacokineticsSingle nucleotide polymorphism

Identifiers

PMID33839311
PMCPMC8636019
OpenAlexW3148499367

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.